{"database":"biostudies-other","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":[null],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-DIXA-014"],"project":["PredTox"],"repository":["biostudies-other"],"additional_accession":[]},"is_claimable":false,"name":"Study FP004BA: Evaluation of the Acute Toxicity, Gene Expression, Protein Expression, Metabolite Production, Clinical Chemistry and Pathology Profile Following an Oral Administration of Compound Bay 16-4749 to Rats","description":"Repeated dose 14-day toxicity study in adult male rats (Rattus norvegicus), Wistar strain, using chemical compound FP004BA, administered daily orally, sponsored by Bayer Schering Pharma AG, funded by European Union Framework Program 6 - Innovative Medicines Initiatives - Integrated Project Predictive Toxicology (EU FP6 InnoMed PredTox: LSHB-CT-2005-518170), The study will examine the gene, protein and metabolite profiles, along with traditional toxicological endpoint information in the liver, kidney, blood and urine of rats 1-14 days after exposure. By design, low doses lie between No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL).","dates":{"release":"2016-06-30T10:26:24Z","modification":"2016-06-30T10:26:18Z","creation":"2016-06-01T12:12:27Z"},"accession":"S-DIXA-014","cross_references":{}}